Search

Your search keyword '"L. Zatarain Barron"' showing total 17 results
Start Over Author "L. Zatarain Barron"
17 results on '"L. Zatarain Barron"'

1. P48.09 Body Mass Index Predicts Benefit From Adding Metformin to EGFR-TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT

Author

Saikrishna S. Yendamuri, L. Zatarain Barron, Jenny G. Turcott, Oscar Arrieta, Rafael Rosell, Feliciano Barrón, Maritza Ramos, and A. Cardona Zorrilla

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung, business.industry, medicine.disease, law.invention, Metformin, Egfr tki, medicine.anatomical_structure, Randomized controlled trial, law, Internal medicine, medicine, Adenocarcinoma, In patient, business, Body mass index, medicine.drug
Published
2021

2. P70.08 Allelic Frequencies of Population Markers Correlate with KRAS G12C Prevalence: Considerations for Ancestries and Molecular Epidemiology

Author

Tatiana Gamez, July Rodriguez, Christian Rolfo, Rafael Rosell, A. Cardona Zorrilla, L. Zatarain Barron, Alejandro Ruiz-Patiño, C. Sotelo, C. Martin, Juan Esteban Garcia-Robledo, N.D. Santoyo Sarmiento, Jorge Otero, L.L. Rojas Puentes, Maritza Bermudez, Hernán Carranza, Pilar Archila, Luis Corrales, Oscar Arrieta, Carlos Vargas, and J. Avila Coy

Subjects
Pulmonary and Respiratory Medicine, Genetics, education.field_of_study, Oncology, Molecular epidemiology, business.industry, Population, medicine, KRAS, Allele, education, medicine.disease_cause, business
Published
2021

3. P70.01 KRAS G12C Mutations Among NSCLC Patients Present With a High Intrerregional Variation, Indicating a Population Substructure

Author

Christian Rolfo, A. Cardona Zorrilla, C. Sotelo, Juan Esteban Garcia-Robledo, Hernán Carranza, Rafael Rosell, C. Martin, July Rodriguez, Alejandro Ruiz-Patiño, Luis Corrales, Jorge Otero, L.L. Rojas Puentes, N.D. Santoyo Sarmiento, Oscar Arrieta, Carlos Vargas, J. Avila Coy, Pilar Archila, Tatiana Gamez, Maritza Bermudez, and L. Zatarain Barron

Subjects
Pulmonary and Respiratory Medicine, Genetics, education.field_of_study, Variation (linguistics), Oncology, business.industry, Population, medicine, Substructure, KRAS, education, medicine.disease_cause, business
Published
2021

4. P1.12 Real World Characterization and Treatment Patterns of Patients with Thymic Carcinoma: Lessons from a Latin American Collaborative Study (CLICaP-LATimus)

Author

Rosa Rosell, M. Corassa, Pilar Archila, Patricia Rioja, Luisa Ricaurte, L. Zatarain Barron, L. Corrales-Rodriguez, S. Lozano, Alejandro Ruiz-Patiño, Jordi Remon, R. Ruiz, T. Soria, Oscar Arrieta, Carlos Vargas, Luis Mas, M. Bravo, J. Ávila, Ana Karina Patané, Jorge Otero, C. Sotelo, Andrés Felipe Cardona, Hernán Carranza, Feliciano Barrón, D. Mayorga, C. Martin, July Rodriguez, Helano C. Freitas, and V. Cordeiro De Lima

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Latin Americans, business.industry, Internal medicine, medicine, medicine.disease, business, Thymic carcinoma
Published
2019

5. PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms

Author

J. Ávila, Luis Mas, Feliciano Barrón, L. Corrales-Rodriguez, Helano C. Freitas, C. Martin, Rosa Rosell, C. Sotelo, Pilar Archila, L. Zatarain Barron, Andrés Felipe Cardona, Alejandro Ruiz-Patiño, Carlos Vargas, V. Cordeiro De Lima, Hernán Carranza, Oscar Arrieta, D. Mayorga, July Rodriguez, Jorge Otero, and Luisa Ricaurte

Subjects
Pulmonary and Respiratory Medicine, First line treatment, Oncology, Bevacizumab, Egfr mutation, business.industry, medicine, Cancer research, business, medicine.drug, EGFR inhibitors
Published
2019

6. P1.10 Survival of Thymoma Is Extensive in Latin-American Patients: Results from over 10 Years of Experience (CLICaP-LATimus)

Author

C. Sotelo, Jorge Otero, Hernán Carranza, Andrés Felipe Cardona, D. Mayorga, Helano C. Freitas, Rosa Rosell, Carlos Vargas, M. Bravo, C. Martin, Alejandro Ruiz-Patiño, M. Corassa, Pilar Archila, Patricia Rioja, J. Ávila, V. Cordeiro De Lima, Luisa Ricaurte, S. Lozano, Jordi Remon, L. Corrales-Rodriguez, Ana Karina Patané, T. Soria, Luis Mas, Oscar Arrieta, R. Ruiz, Feliciano Barrón, July Rodriguez, and L. Zatarain Barron

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Thymoma, Latin Americans, Oncology, business.industry, General surgery, Medicine, business, medicine.disease
Published
2019

7. P2.23 Characterization of Hispanic Patients Who Experienced Hyperprogression During Treatment for Advanced NSCLC with Immunotherapy

Author

C. Sotelo, Oscar Arrieta, Hernán Carranza, Manglio Rizzo, R. Ruiz Mendoza, Feliciano Barrón, L. Zatarain Barron, Rosa Rosell, July Rodriguez, C. Bas, Carlos Ortiz, Luisa Ricaurte, F. Perazzo, C. Pupareli, Christian D. Rolfo, C. Martin, Jorge Otero, Luis Mas, Pilar Archila, O. Carranza, L. Corrales-Rodriguez, L. Lupinacci, M.A. Bravo-Garzón, P. Laguado, L. Rojas, Luis E. Raez, Carlos Vargas, Andrés Felipe Cardona, Luis Eduardo Pino, and Alejandro Ruiz-Patiño

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Internal medicine, Medicine, Immunotherapy, business
Published
2019

8. P2.03 Normalization of Carcinoembryonic Antigen Levels Are Associated with a Survival Improvement in Advanced Non-Small Cell Lung Cancer Patients

Author

M.P. Peralta Álvarez, A. Pereira-García, Oscar Arrieta, E. Varela Santoyo, R. Sánchez Reyes, C. Martin, L. Zatarain Barron, Andrés Felipe Cardona, Feliciano Barrón, L. Corrales-Rodriguez, and Leticia Cabrera

Subjects
Pulmonary and Respiratory Medicine, Oncology, Normalization (statistics), medicine.medical_specialty, biology, business.industry, medicine.disease, Carcinoembryonic antigen, Internal medicine, medicine, biology.protein, Non small cell, Lung cancer, business
Published
2019

9. P2.25 Immunotherapy at Any Line of Treatment Improves Survival in Hispanic Patients with Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) Compared with Chemotherapy (Quijote-CLICaP)

Author

L. Zatarain Barron, Carlos Vargas, Rosa Rosell, Luisa Ricaurte, Feliciano Barrón, Manglio Rizzo, P. Laguado, R. Ruiz Mendoza, Christian D. Rolfo, C. Sotelo, C. Bas, O. Carranza, L. Rojas, Pilar Archila, Hernán Carranza, Oscar Arrieta, L. Lupinacci, Luis E. Raez, Jorge Otero, Luis Eduardo Pino, July Rodriguez, Andrés Felipe Cardona, C. Pupareli, C. Martin, M.A. Bravo-Garzón, Alejandro Ruiz-Patiño, Luis Mas, Carlos Ortiz, F. Perazzo, and L. Corrales-Rodriguez

Subjects
Pulmonary and Respiratory Medicine, Oncology, Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, non-small cell lung cancer (NSCLC), Immunotherapy, medicine.disease, Internal medicine, Medicine, Line (text file), business
Published
2019

10. P2.22 Immunotherapy-related Thrombosis: Considerations and Associated Factors in Non-small Cell Lung Cancer (NSCLC) Patients

Author

Luisa Ricaurte, L. Zatarain Barron, July Rodriguez, Rosa Rosell, J. Ávila, Carlos Vargas, Oscar Arrieta, C. Martin, L. Corrales-Rodriguez, Pilar Archila, Andrés Felipe Cardona, Alejandro Ruiz-Patiño, Feliciano Barrón, Helano C. Freitas, C. Sotelo, Hernán Carranza, Jorge Otero, V. Cordeiro De Lima, D. Mayorga, and Luis Mas

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Internal medicine, medicine, non-small cell lung cancer (NSCLC), Immunotherapy, medicine.disease, business, Thrombosis
Published
2019

11. P2.24 Lung Immune Prognostic Index in Patients with Non-small Cell Lung Cancer Treated with Either Chemo or Immunotherapy

Author

L.A. Ramírez Tirado, Oscar Arrieta, Dariel López, B. Mota, Feliciano Barrón, L. Zatarain Barron, and M.P. Peralta Álvarez

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung, business.industry, medicine.medical_treatment, Immunotherapy, medicine.disease, medicine.anatomical_structure, Immune system, Internal medicine, Medicine, In patient, Non small cell, business, Lung cancer
Published
2019

12. PD2.03 Exploration of Factors Relating to Immune Response in Patients Treated with Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (NSCLC)

Author

Carlos Vargas, Andrés Felipe Cardona, C. Sotelo, Luisa Ricaurte, Rosa Rosell, Oscar Arrieta, Hernán Carranza, L. Zatarain Barron, D. Mayorga, Pilar Archila, Helano C. Freitas, V. Cordeiro De Lima, Alejandro Ruiz-Patiño, C. Martin, Jorge Otero, J. Ávila, Feliciano Barrón, Luis Mas, July Rodriguez, and L. Corrales-Rodriguez

Subjects
Pulmonary and Respiratory Medicine, Immune system, Oncology, business.industry, Immune checkpoint inhibitors, Cancer research, Medicine, non-small cell lung cancer (NSCLC), In patient, business, medicine.disease
Published
2019

13. PD1.05 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced Non-small-cell Lung Cancer (CLICAP-ABs)

Author

J. Ávila, Alejandro Ruiz-Patiño, C. Martin, Rosa Rosell, July Rodriguez, Pilar Archila, L. Corrales-Rodriguez, C. Sotelo, Helano C. Freitas, Jorge Otero, Carlos Vargas, Hernán Carranza, D. Mayorga, Feliciano Barrón, V. Cordeiro De Lima, Andrés Felipe Cardona, L. Zatarain Barron, and Luis Mas

Subjects
Pulmonary and Respiratory Medicine, Oncology, business.industry, Immune checkpoint inhibitors, medicine, Cancer research, Non small cell, Antibiotic use, Lung cancer, medicine.disease, business
Published
2019

14. P2.26 Budget Impact Analysis of Immunotherapy as Second-line Treatment of NSCLC at MX's National Institute of Cancer

Author

M.F. Chávez Millan, L. Zatarain Barron, D.I. Palafox Torres, L.A. Ramírez Tirado, L.M. Ruíz-Godoy, Oscar Arrieta, J.Á. Paladio Hernández, A.A. Meneses-García, J. De La Garza Salazar, Feliciano Barrón, Andrés Felipe Cardona, and M.P. Peralta Álvarez

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Second line treatment, business.industry, medicine.medical_treatment, Cancer, Budget impact, Immunotherapy, medicine.disease, Internal medicine, medicine, business
Published
2019

15. Systemic management of malignant meningioma: A comparative survival and molecular marker analysis between ocreotide in combination with everolimus compared to sunitinib

Author

Leonardo Rojas, Hernando Cifuentes, Alejandro Ruiz-Patiño, Enrique Jiménez, Oscar Arrieta, Fernando Hakim, Carmen Balana, L.E. Pino Villareal, A. Cardona Zorrilla, L. Zatarain-Barron, Sonia Bermúdez, Diego Pineda, Nicolás Useche, F. Ramon, and Juan Armando Mejía

Subjects
Oncology, medicine.medical_specialty, Everolimus, Malignant meningioma, business.industry, Sunitinib, Hematology, chemistry.chemical_compound, chemistry, Internal medicine, Molecular marker, medicine, business, medicine.drug
Published
2018

16. Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country.

Author

Cifuentes C, Lombana M, Vargas H, Laguado P, Ruiz-Patiño A, Rojas L, Navarro U, Vargas C, Ricaurte L, Arrieta O, Zatarain-Barron L, Zapata L, González G, Ortiz C, Bernal L, Restrepo JG, Viola L, Grosso F, Zapata R, Mantilla W, Carranza H, Bustillo I, Llinas N, Duarte R, Rodríguez J, Archila P, Ávila J, Bermúdez M, Gámez T, Sotelo C, Otero J, Forero E, Lema M, Limpias C, Ordóñez-Reyes C, Mejía S, Rolfo C, Rosell R, and Cardona AF

Subjects
Humans, Female, Middle Aged, Male, Retrospective Studies, Mutation, Genomics, High-Throughput Nucleotide Sequencing, Developing Countries, Lung Neoplasms pathology
Abstract

Purpose: Identifying actionable oncogenic mutations have changed the therapeutic landscape in different types of tumors. This study investigated the utility of comprehensive genomic profiling (CGP), a hybrid capture-based next-generation sequencing (NGS) assay, in clinical practice in a developing country., Methods: In this retrospective cohort study, CGP was performed on clinical samples from patients with different solid tumors recruited between December 2016 and November 2020, using hybrid capture-based genomic profiling, at the individual treating physicians' request in the clinical care for therapy decisions. Kaplan-Meier survival curves were estimated to characterize the time-to-event variables., Results: Patients median age was 61 years (range: 14-87 years), and 64.7% were female. The most common histological diagnosis was lung primary tumors, with 90 patients corresponding to 52.9% of the samples (95% CI 45.4-60.4%). Actionable mutations with FDA-approved medications for specific alterations correspondent to tumoral histology were identified in 58 cases (46.4%), whereas other alterations were detected in 47 different samples (37.6%). The median overall survival was 15.5 months (95% CI 11.7 months-NR). Patients who were subjected to genomic evaluation at diagnosis reached a median overall survival of 18.3 months (95% CI 14.9 months-NR) compared to 14.1 months (95% CI 11.1 months-NR) in patients who obtained genomic evaluation after tumor progression and during standard treatment ( P = .7)., Conclusion: CGP of different types of tumors identifies clinically relevant genomic alterations that have benefited from targeted therapy and improve cancer care in a developing country to guide personalized treatment to beneficial outcomes of cancer patients.

Published
2023
Full Text
View/download PDF

17. Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019-Infected Patients With Lung Cancer.

Author

Rolfo C, Cardona AF, Ruiz-Patiño A, Ariza S, Zatarain-Barron L, Pino LE, Viola L, Russo A, Rojas L, Ricaurte L, and Arrieta O

Subjects
COVID-19, Female, Humans, Male, Middle Aged, Pandemics, SARS-CoV-2, B7-H1 Antigen antagonists & inhibitors, Betacoronavirus, Coronavirus Infections complications, Lung Neoplasms drug therapy, Pneumonia, Viral complications, Skin Diseases etiology
Abstract

A new coronavirus, named severe acute respiratory syndrome-coronavirus-2 by the WHO, has rapidly spread around the world since its first reported case in late December of 2019 from Wuhan, the People's Republic of China. As of mid-April 2020, this virus has affected more than 180 countries and territories, infecting more than 1,650,000 individuals and causing over 100,000 deaths. With approximately 20 million new cases globally per year, cancer affects a substantial portion of the population. Individuals affected by cancer are more susceptible to infections owing to coexisting chronic diseases (cardiovascular, pulmonary, and diabetes), overall poor health status, and systemic immunosuppressive states caused by both cancer and the anticancer treatment. As a consequence, patients with malignancies, especially those with lung cancer who develop coronavirus disease 2019, experience more difficult outcomes. A recent multicenter study carried out by the Hubei Anti-Cancer Association has also documented that patients with lung cancer had an increased risk of death, intensive care unit requirement, risk of presenting severe or critical symptoms, and use of invasive mechanical ventilation. Here, we present two representative cases of patients with lung cancer and coronavirus disease 2019 without respiratory compromise and with atypical and severe skin manifestations-findings that could be influenced by the long-term use of anti-programmed cell death protein 1 antibody., (Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results